TX HB 7: Relating to prohibitions on the manufacture and provision of abortion-inducing drugs, including the jurisdiction of and effect of certain judgments by courts within and outside this state with respect to the manufacture and provision of those drugs, and to protections from certain counteractions under the laws of other states and jurisdictions; authorizing qui tam actions.
Texas HB 7 prohibits the manufacture and provision of abortion-inducing drugs, with extraterritorial reach and qui tam enforcement. This directly impacts pharmaceutical manufacturers of mifepristone, misoprostol, and other abortion-inducing drugs, including API and contract manufacturers, even if located outside Texas. The law creates liability for out-of-state conduct and allows private lawsuits.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) involved in manufacturing or distributing abortion-inducing drugs (mifepristone, misoprostol, etc.) should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective immediately upon passage (likely 2025 session). Monitor enactment date.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Texas HB 7 prohibits manufacturing, providing, or distributing abortion-inducing drugs, with broad jurisdiction over out-of-state actors and qui tam enforcement. It also restricts FDA-approved drug labels and interstate commerce protections.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) involved in manufacturing or distributing abortion-inducing drugs (mifepristone, misoprostol, etc.)
What you must do
Assess whether your product portfolio includes abortion-inducing drugs. If so, evaluate legal risks of manufacturing, distributing, or selling in Texas or to Texas residents. Consider halting shipments to Texas, relabeling, or seeking legal counsel.
Deadline
Effective immediately upon passage (likely 2025 session). Monitor enactment date.
Source: https://capitol.texas.gov/BillLookup/History.aspx?LegSess=892&Bill=HB7
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Process for FDA Data Requests To Inform Certain Over-the-Counter Monograph Drug Activities; Procedure
- US-CONGRESS BILLS-119hr9661ih: Expedited Access to Biosimilars Act
- FDA drafts new ultra-rare disease therapy guidance - European Pharmaceutical Review
- FDA Proposal Would Leave Semaglutide, Tirzepatide, and Liraglutide Off 503B Bulks List - The National Law Review
- IL HB0004: MEDICAID-PHARMACY SERVICES